Radiopharmaceuticals
•19 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (19)
%
| Company | Market Cap | Price |
|---|---|---|
|
The radiopharmaceuticals/radioligand therapy modality aligns with the Radiopharmaceuticals thematic tag.
|
$120.19B |
$98.46
|
|
Radiopharmaceuticals (Flyrcado, Vizamyl) form a major diagnostic product category.
|
$32.51B |
$71.01
-4.05%
|
|
Acquisition of Atomic Alchemy to produce radioisotopes and VIPR medical/industrial isotopes.
|
$20.49B |
$147.16
+6.88%
|
|
BWXT's Medical segment produces radiopharmaceuticals and nuclear medicine isotopes used in diagnostics and therapy.
|
$17.37B |
$190.08
-2.82%
|
|
Radium radiopharmaceutical isotopes development (TAT) using Mill streams; potential commercial isotope production.
|
$3.74B |
$16.71
-4.57%
|
|
Bicycle Radioconjugates (BRC) are radiopharmaceuticals targeting tumors for imaging and radioisotope delivery.
|
$576.19M |
$8.32
-7.25%
|
|
MNPR-101 radiopharmaceutical platform spanning imaging (Zr-89) and radiotherapy conjugates.
|
$537.04M |
$87.82
-14.34%
|
|
Radiopharmaceuticals platform and GD2-SADA program.
|
$389.89M |
$8.61
|
|
Core business: development and commercialization of radiopharmaceuticals for diagnostic imaging and targeted alpha therapies.
|
$360.75M |
$4.86
+15.71%
|
|
Development of Tau and alpha-synuclein PET tracers makes Radiopharmaceuticals a direct product category.
|
$354.43M |
$3.55
+0.28%
|
|
Radio-DARPin therapy platform delivering radiopharmaceuticals (e.g., 212Pb) with Orano Med partnership.
|
$126.14M |
$3.80
+1.06%
|
|
Operates a radiopharmaceutical services platform with biodistribution and therapeutic testing.
|
$90.10M |
$6.54
-0.46%
|
|
Actinium's direct products are radiopharmaceuticals (ARC radiotherapies) such as Actimab-A and ATNM-400, and its pipeline centers on radiopharmaceutical oncology.
|
$46.48M |
$1.49
-1.97%
|
|
Company directly develops radiopharmaceuticals for diagnostic and therapeutic oncology applications.
|
$46.41M |
$7.03
-5.64%
|
|
Radiopharmaceuticals category covering radioactive agents used in oncology; aligns with RDGL's Y-90 therapy approach.
|
$40.84M |
$0.09
+0.90%
|
|
PSTV directly develops radiopharmaceutical therapy using Rhenium-186 nanoliposomes (REYOBIQ) for CNS tumors.
|
$24.42M |
$0.72
-7.07%
|
|
Cellectar directly develops radiopharmaceuticals and radioconjugates for cancer therapy, including its lead iopofosine I-131 and next-generation radiopharmaceuticals.
|
$7.13M |
$4.64
-3.73%
|
|
Advancing radiopharmaceutical products used in cancer diagnosis/therapy, i.e., radiopharmaceuticals.
|
$1.67M |
$3.80
+6.74%
|
|
Core business: manufacturing and distribution of radiopharmaceuticals, including FDA-approved I-131 products.
|
$518499 |
$0.05
-7.75%
|
Loading industry metrics...
Loading comparison data...
